阅读说明：本技术 从柳属植物中分离的用于癌症疗法的脱氢柳皮苷环二聚体及其衍生物 (Dehydroepiloside cyclic dimers and derivatives thereof isolated from Salix species for cancer therapy ) 是由 M·H·比尔 J·L·沃德 Y·吴 M·米凯利斯 于 2020-01-29 设计创作，主要内容包括：本文描述了包含脱氢柳皮苷的二聚体或其衍生物、同系物、立体异构体、前药或药用盐的化合物。在具体的实施方案中,该二聚体是Diels-Alder反应的结果。本文还描述了包含化合物的组合物及其治疗疾病的用途。(Described herein are compounds comprising a dimer of dehydroepirubin, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof. In a specific embodiment, the dimer is the result of a Diels-Alder reaction. Also described herein are compositions comprising the compounds and their use to treat diseases.)

1. A compound comprising a deoxysalicin dimer, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof, preferably wherein the dimer is the result of a Diels-Alder reaction.

2. A compound of formula I, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

R¹-L-R²

formula I

Wherein L is a linking unit, R¹And R²Each independently selected from the group consisting of formula III,

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, preferably wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl, preferably wherein R is³、R⁴、R⁵And R⁶Each is H.

3. The compound of claim 2, wherein

(a)R¹Is of formula IIIA:

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, preferably wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl, preferably wherein R is³、R⁴、R⁵And R⁶Each is H, or

(b)R¹Is of formula IIIB:

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, preferably wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl, preferably wherein R is³、R⁴、R⁵And R⁶Each is H.

4. A compound according to claim 2 or 3, wherein

(a)R²Is of formula IIIC:

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, preferably wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl, preferably wherein R is⁷、R⁸、R⁹And R¹⁰Each is H, or

(b)R²Is of formula IIID:

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, preferably wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl, preferably wherein R is⁷、R⁸、R⁹And R¹⁰Each is H.

5. The compound according to any one of claims 2 to 4, wherein L comprises a cyclic structure, preferably wherein L is the result of a Diels-Alder reaction and/or wherein L comprises a tricyclodecadiene derivative.

6. The compound according to any one of claims 2 to 5, wherein L is selected from

(a) Formula IIA:

wherein R is¹²And R¹³Each independently selected from H and OH, preferably, wherein R is¹²And R¹³Is OH, or

(b) Formula IIB:

wherein R is¹⁴And R¹⁵Each independently selected from H and OH, preferably, wherein R is¹²And R¹³Is OH.

7. A compound of formula IIC, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof:

wherein R is¹⁶And R¹⁷Each independently selected from H, OH and formula III, provided that R¹⁶And R¹⁷Is selected from formula III, preferably, wherein R is¹⁶And R¹⁷Each independently selected from formula III, and

wherein R is¹²And R¹³Each independently selected from H and OH.

8. A compound of formula IID, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof:

wherein R is¹⁸And R¹⁹Each independently selected from H, OH and formula III, provided that R¹⁸And R¹⁹Is selected from formula III, preferably, wherein R is¹⁸And R¹⁹Each independently selected from formula III, and

wherein R is¹⁴And R¹⁵Each independently selected from H and OH.

9. A compound selected from

(a) Formula VII or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein R is³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, and

wherein R is¹²And R¹³Each independently selected from H and OH, preferably, wherein R is¹⁴And R¹⁵Each is OH, or

(b) Formula VIII or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein R is³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, and

wherein R is¹⁴And R¹⁵Each independently selected from H and OH, preferably, wherein R is¹⁴And R¹⁵Each is OH.

10. The compound of claim 9, wherein R³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl, preferably wherein R is³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each is H.

11. A compound of formula IX, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl,

wherein R is¹¹Selected from (i) H, (ii) OH and (III) formula III,

wherein R is¹³Selected from H and OH.

12. The compound of claim 11, wherein R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl, preferably wherein R is⁷、R⁸、R⁹And R¹⁰Each is H.

13. A compound of formula X, XI, XII, XIII, XIV, XV, XVI, XVII or XVIII, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

14. A composition comprising a compound according to any preceding claim.

15. A composition according to claim 14, wherein the composition comprises a compound of formula VI, VIII or IX, most preferably a compound of formula VII, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

16. A composition as in claim 14, wherein the composition comprises a compound of formula X, XI or XII.

17. The composition of claim 14, wherein the composition comprises a compound of formula X, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof

18. A composition according to any one of claims 14 to 17 for use in therapy.

19. Use of a composition according to any one of claims 14 to 17 for the treatment of a disease.

20. Use of a composition according to any one of claims 14 to 17 in the manufacture of a medicament for the treatment of a disease.

21. A method of treating a disease, wherein the method comprises administering to a patient having a disease a therapeutically effective amount of a composition according to any one of claims 14 to 17.

22. The composition of claim 18, wherein therapy comprises treatment of a disease, the use of claim 19 or 20, or the method of claim 21, wherein the disease is cancer, preferably wherein the cancer is primary or secondary (metastatic) cancer and/or wherein the cancer is drug resistant cancer.

23. The composition of claim 22, wherein the cancer is selected from neuroblastoma, breast cancer, esophageal cancer, or ovarian cancer.

24. A method for producing a compound according to any one of claims 1 to 23, wherein the method comprises extracting the compound from a Salix plant, preferably wherein the method comprises extracting the compound from leaf or stem tissue of a Salix plant, preferably wherein Salix is selected from (i) Salix integra, Salix matsudana, Salix fluviatilis, Salix willow, Salix serpens, Salix paraqua, Salix capsici, or Salix adhenophylla, or (ii) hybrids of Salix gordonii, Salix matsudana, Salix fluviatilis, Salix serpens, Salix capsici, or Salix adhenophylla.

25. The method of claim 24, wherein the salix genus is salix integra or hybrids thereof.

Technical Field

The present invention relates to novel compounds and their use in therapy, in particular for the treatment of cancer.

Background

Cancer is a disease that affects millions of people worldwide each year. Although there are many effective therapies for treating cancer, there are a large number of cancers that have no treatment, or the current treatments are largely ineffective against these cancers. In combination with the large number of different types of cancer that are currently known, this means that there is a great need for new therapies.

It is therefore an object of the present invention to seek to alleviate the above problems.

Disclosure of Invention

According to one aspect of the present invention, there is provided a compound comprising a dehydrosalicin (dehydrosalicin) dimer, or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.

Preferably, the dimer is the result of a Diels-Alder reaction.

According to a further aspect of the present invention there is provided a compound of formula I, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to a compound of formula I means a compound having the structure:

wherein L is a linking unit, R¹And R²Each independently selected from formula III.

In the present specification, reference to formula III means:

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl (cinnamyl).

Preferably, R³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl.

Preferably, R³、R⁴、R⁵And R⁶Each is H.

For convenience, table 1 provides the structures of some of the groups mentioned herein.

TABLE 1

Preferably, R¹Is of formula IIIA:

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl.

Preferably, R³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl.

Preferably, R³、R⁴、R⁵And R⁶Each is H.

Preferably, R¹Is of formula IIIB:

wherein R is³、R⁴、R⁵And R⁶Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl. Preferably, R³、R⁴、R⁵And R⁶Each independently selected from (i) H and (ii) acetyl. Preferably, R³、R⁴、R⁵And R⁶Each is H.

Preferably, R²Is of formula IIIC:

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each is H.

Preferably, R²Is of formula IIID:

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each is H.

Preferably, L comprises a cyclic structure.

Preferably, L is the result of a Diels-Alder reaction.

Preferably, L comprises a core element produced by a Diels-Alder reaction.

Preferably, L comprises a tricyclododiene (tricyclodicodediene) derivative, preferably a substituted derivative, preferably wherein the cycloalkene is substituted with at least one group selected from OH, carbonyl.

Preferably, L is selected from formula II a or formula II B.

In the present specification, reference to formula II a means:

wherein R is¹²And R¹³Each independently selected from H and OH.

Preferably, R¹²And R¹³Each is OH.

In the present specification, reference to formula II B means:

wherein R is¹⁴And R¹⁵Each independently selected from H and OH.

Preferably, R¹⁴And R¹⁵Each is OH.

According to another aspect of the present invention there is provided a compound of formula il C, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to a compound of formula il C refers to a compound having the structure:

wherein R is¹⁶And R¹⁷Each independently selected from H, OH and formula III, provided that R¹⁶And R¹⁷Is selected from formula III, and

wherein R is¹²And R¹³Each independently selected from H and OH.

Preferably, R¹⁶And R¹⁷Selected from formula III.

Preferably, R¹⁶Or R¹⁷Selected from formula III.

Preferably, R¹⁶Is H, R¹⁷Selected from formula III.

Preferably, R¹²And R¹³Each is OH.

According to another aspect of the present invention there is provided a compound of formula il D, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to a compound of formula II D means a compound having the structure:

wherein R is¹⁸And R¹⁹Each independently selected from H, OH and formula III, provided that R¹⁸And R¹⁹Is selected from formula III, and

wherein R is¹⁴And R¹⁵Each independently selected from H and OH.

Preferably, R¹⁸And R¹⁹Selected from formula III.

Preferably, R¹⁸Or R¹⁹Selected from formula III.

Preferably, R¹⁴And R¹⁵Each is OH.

Preferably, the present invention relates to a compound of formula VII or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula VII means:

wherein R is³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, and

wherein R is¹²And R¹³Each independently selected from H and OH.

Preferably, R³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl.

Preferably, R³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each is H.

Preferably, R¹²And R¹³Each is OH.

Preferably, the present invention relates to a compound of formula VIII or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to formula VIII means:

wherein R is³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl, and

wherein R is¹⁴And R¹⁵Each independently selected from H and OH.

Preferably, R³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl.

Preferably, R³、R⁴、R⁵、R⁶、R⁷、R⁸、R⁹And R¹⁰Each is H.

Preferably, R¹⁴And R¹⁵Each is OH.

Preferably, the present invention relates to a compound of formula IX, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula IX means:

wherein R is⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl.

Wherein R is¹¹Selected from (i) H, (ii) OH and (III) formula III.

Wherein R is¹³Selected from H and OH.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each independently selected from (i) H and (ii) acetyl.

Preferably, R⁷、R⁸、R⁹And R¹⁰Each is H. Preferably, R¹³Is H.

Preferably, R¹¹Is H or OH. Preferably, R¹¹Is OH.

Preferably, the present invention relates to a compound of formula X or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula X means:

preferably, the present invention relates to a compound of formula XI, or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to formula XI means:

preferably, the present invention relates to a compound of formula XII, or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula XII means:

preferably, the present invention relates to a compound of formula XIII or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula XIII means:

preferably, the present invention relates to a compound of formula XIV or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to formula XIV means:

preferably, the present invention relates to a compound of formula XV or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present description, reference to formula XV means:

preferably, the present invention relates to a compound of formula XVI or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present description, reference to formula XVI means:

preferably, the present invention relates to a compound of formula XVII or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present description, reference to formula XVII means:

preferably, the present invention relates to a compound of formula XVII or a derivative, homolog, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present description, reference is made to formula xviii to mean:

according to another aspect of the present invention, there is provided a compound of formula XIX or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In this specification, reference to formula XIX means:

wherein R is¹Selected from (i) H, (ii) acetyl, (iii) benzoyl, (iv) o-or p-coumaroyl, (v) cinnamoyl.

Preferably, the present invention relates to a compound of formula XX or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to formula XX means:

preferably, the derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof is a therapeutically effective derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

According to another aspect of the present invention there is provided a composition comprising a compound as described herein, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

Preferably, the composition comprises a compound of formula VII, VIII or IX (most preferably, a compound of formula VII), or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

Preferably, the composition comprises a compound of formula X, XI or XII (most preferably, a compound of formula X), or a derivative, homolog, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.

Preferably, the composition is a pharmaceutical composition.

Preferably, the composition is a therapeutic composition.

Preferably, the composition comprises one or more pharmaceutically acceptable carriers, diluents or excipients.

According to another aspect of the invention, there is provided a composition as described herein for use in therapy.

According to other aspects of the invention, there is provided the use of a composition as described herein for the treatment of a disease.

According to another aspect of the present invention there is provided the use of a composition according to the present invention in the manufacture of a medicament for the treatment of a disease.

According to other aspects of the invention, there is provided a method of treating a disease, wherein the method comprises administering to a patient having a disease a therapeutically effective amount of a composition described herein.

Preferably, the therapy comprises treating the disease.

Preferably, treating a disease comprises administering a therapeutically effective amount of a composition of the invention to a patient suffering from the disease.

Preferably, the disease is cancer.

Preferably, the cancer is a primary or secondary (metastatic) cancer.

Preferably, the cancer is a drug resistant cancer. In this regard, it is to be understood that reference to "drug-resistant cancer" refers to a cancer that previously exhibited resistance to treatment with another therapeutic composition, e.g., a cancer that was not successfully treated with another therapeutic composition.

Preferably, the cancer is resistant to an anti-microtubule agent (preferably, an anti-microtubule alkaloid agent).

Preferably, the cancer is resistant to vinca alkaloids.

Preferably, the cancer is resistant to vincristine.

Preferably, the cancer is selected from neuroblastoma, breast cancer, esophageal cancer or ovarian cancer.

Preferably, the neuroblastoma is a metastatic neuroblastoma in the bone marrow.

Preferably, the neuroblastoma is a vincristine-resistant metastatic neuroblastoma in the bone marrow.

Preferably, the breast cancer is invasive ductal carcinoma.

Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

Preferably, the ovarian cancer is high grade ovarian serous adenocarcinoma or ovarian cystadenocarcinoma.

Preferably, the cancer is a metastatic cancer.

Preferably, the subject is a mammal.

Preferably, the subject is a human.

Preferably, the composition of the invention comprises one or more additional active compounds. Preferably, the one or more additional active compounds are therapeutically active compounds, e.g. co-delivered with the compositions described herein in the form of additional therapeutic compounds.

According to another aspect of the present invention there is provided a method for the production of a compound as described herein, wherein the method comprises extracting the compound from a plant of the genus salix.

Preferably, the method comprises extracting the compound from the leaf or stem tissue of a plant of the genus salix.

Preferably, the Salix is selected from the group consisting of hybrids of (i) Salix integra (Salix miyabena), Salix pubescens (Salix dasycarpos), Salix fluviana (Salix gilgiana), Salix willow (Salix gmelinii), Salix paradoxa (Salix rephenias), Salix capsicum annuum (Salix capsica), Salix sicaria (Salix rehderiana), Salix pseudopterocarina (S.rossica), S.glaucophylloides, or Salix adenophylla, or (ii) Salix alba, Salix trichocarpa, Salix fluviana, Salix alba, Salix paradoxa, Capsicum annuum, Salix siccus, Salix pseudopterocarpum, S.glaucophylloides, or Salix adenophylla.

Preferably, the Salix genus is selected from (i) Salix integra, Salix matsudana, Salix fluviatilis, Salix twig and leaf, Salix serpens, Salix capsici, or Salix adhenophylla, or (ii) a hybrid of Salix mongolica, Salix matsudana, Salix fluviatilis, Salix matsudana, or Salix adhenophylla.

Preferably, the Salix species is Salix integra or a hybrid of Salix integra.

Preferably, the salix genus is salix integra (s. miyabena Seemen) or a hybrid of salix integra.

Preferably, the salix genus is salix integra (s. miyabeans purpurecens) or a hybrid of salix integra.

Preferably, the Salix species is Salix species or a hybrid of Salix species.

Preferably, the salix genus is salix chuanxiong or a hybrid of salix chuanxiong.

Preferably, the Salix species is RRes710-27, RR09102 hybrid [ NWC607S. Dianthus altissima x RR05337(Aud x pseudo-tamarind) ].

Preferably, salix is a hybrid breeding line of salix integra (RR10347) resulting from the hybridization of NWC941 (salix integra) with RR05326(Resolution x salix pseudohayata).

Preferably, the Salix is willow breeding line RR 10147.

RR10147 was developed as part of the Biomass improvement program of the Rosensland Research institute. The hybrid lines included tamarind (NWC577) and s.glaucophylloides (NWC 944) in two parents [ RR07187(944 s.glaucophylloides × 577 "77056") ] x RR07188(944 s.glaucophylloides × 577 "77056") ].

In this specification, embodiments have been described in a manner that enables a clear and concise specification to be written, but it is intended and should be understood that various combinations and subcombinations of the various embodiments may be made without departing from the invention. For example, it should be understood that all of the preferred features described herein apply to all aspects of the invention.

Drawings

Embodiments of the invention will now be described with reference to the accompanying drawings, in which:

FIG. 1 shows the structure of a dimeric compound isolated from Salix integra;

FIG. 2 shows a reverse phase HPLC analysis of Salix alba leaf extract, showing that the peak of Salix alba (miyabeacin) is reached at 57.93 minutes;

FIG. 3 shows a total ion chromatogram of an LC-MS analysis (negative ion mode) of purified oxytetracycline;

FIG. 4 shows a mass spectrum of oxytetracycline at m/z 843.23529 with a retention time of 25.31 minutes (negative ion mode);

FIG. 5 shows the MS-MS spectrum (negative ion mode) of m/z 843.23529(25.31 min);

FIG. 6 shows the MS-MS spectrum (negative ion mode) of m/z 421.11404(25.31 min);

FIG. 7 shows a CD₃Method for purifying oxytetracycline in OD¹H-NMR spectrum. It shows an extended region at δ 7.50- δ 3.49;

FIG. 8 shows a CD₃Method for purifying oxytetracycline in OD¹H-¹H COSY NMR spectrum. It shows an extended region at δ 7.51- δ 3.49;

FIG. 9 shows a CD₃Method for purifying oxytetracycline in OD¹³A C-NMR spectrum;

FIG. 10 shows a CD₃Method for purifying oxytetracycline in OD¹³C-DEPT135 spectrum;

FIG. 11 shows a CD₃Method for purifying oxytetracycline in OD¹H-¹³C-HMBC spectrogram;

FIG. 12 shows a reverse phase HPLC analysis of Salix gondii stem extract, indicating that Salix gondii B peaked at 52.11 minutes;

FIG. 13 shows a total ion chromatogram of an LC-MS analysis (negative ion mode) of purified oxytetracycline B;

FIG. 14 shows the mass spectrum (negative ion mode) of oxytetracycline B at m/z 843.23474 with a retention time of 24.34 min;

FIG. 15 shows a total ion chromatogram of an LC-MS analysis (negative ion mode) of purified miyabenol;

FIG. 16 shows the mass spectrum (negative ion mode) of miyabenol at m/z 531.15074 with a retention time of 20.11 min;

FIG. 17 shows a MSMS spectrum (negative ion mode) of miyabenol at m/z 531.15074 with a retention time of 20.11 min;

FIG. 18 shows purified miyabenol in D2O: CD3OD (4:1)¹H-NMR spectrum. It shows an extended region at δ 7.60- δ 3.00;

FIG. 19 shows miyabenol in D2O: CD3OD (4:1)¹H-¹H COSY NMR spectrum; and

FIG. 20 shows miyabenol in D2O: CD3OD (4:1)¹³C NMR spectrum.

Detailed Description

The present invention relates to novel compounds and their use in therapy, in particular for the treatment of cancer.

The compounds described herein are extracted from plants of the genus salix, in particular salix integra or salix pubescens.

Generally, the genetic origin of salix plants is unknown, although they are most abundant in the cold and warm regions of the northern hemisphere (including, e.g., europe, asia, and north america).

With respect to the case of the salix integra mentioned herein, the species is considered to be native to japan and korea.

With respect to the species of salix pubescens referred to herein, this species is believed to be native to siberia.

As regards the hippophae rhynchophylla referred to herein, the species is considered to be native to japan and korea.

With respect to willow species referred to herein, the species is believed to be native to hassaxosteins.

With respect to the stoloniferous species mentioned herein, the species is considered to be native to austria, the porrigo country, belgium, central europe russia, czech savark, denmark, finland, france, germany, uk, irish, the netherlands, norway, portuga, spain, sweden, switzerland south swarfs.

With respect to the pepper willows mentioned herein, the species is considered to be native to zhou asia.

With respect to the Salix adenophylla referred to herein, this species is believed to be native to North America.

With respect to the salix chuanxiong herein, the species is believed to be native to china.

With respect to the pseudotamarix species mentioned herein, the species is believed to be native to europe, western asia and himalayas.

With respect to the Salix glaucophylloides mentioned herein, this species is believed to be native to North America.

In this specification, the term "oxytetracycline" refers to a compound of formula X.

In this specification, the term "oxytetracycline B" refers to a compound of formula XI.

In this specification, the term "miyabenol" refers to a compound of formula XII.

In the present specification, the term "about" means ± 20%, more preferably ± 10%, even more preferably ± 5%, most preferably ± 2%.

As used herein, the term "therapeutically effective amount" refers to an amount of the composition that reduces the severity of and/or improves the severity of at least one condition or symptom caused by the disease in question.

In the present specification, the term "treatment" refers to the therapeutic and/or prophylactic treatment of an existing disease, to prevent the occurrence of the disease. Thus, the methods and compositions of the present invention can be used to treat, prevent, inhibit the progression of, or delay the onset of a disease.

In the present specification, reference to "a compound as described herein" preferably means a compound of any one of formulae I to XX, or a derivative, homologue, stereoisomer, prodrug or pharmaceutically acceptable salt thereof.

In the present specification, reference to "a composition as described herein" means a composition comprising a compound as described herein. Preferably, the composition is a pharmaceutical composition.

Preferably, the composition comprises a therapeutically effective amount of at least one compound described herein or a physiologically acceptable salt thereof.

Preferably, the composition comprises a physiologically acceptable carrier.

In this specification, the term "prodrug" refers to a compound that is biologically inactive, but which, upon metabolism, produces an active therapeutic agent.

In the present specification, the term "derivative" refers to a molecule derived from a compound described herein. For example, such derivatives may be synthetically altered derivatives of these compounds.

In this specification, the term "homologue" refers to a molecule having substantial structural similarity to the compounds described herein.

In this specification, the term "stereoisomer" refers to a molecule having the same molecular formula and sequence of bonded atoms as another molecule, but whose atoms are not spatially oriented in three dimensions.

The compounds and compositions of the invention may be formulated for clinical use as pharmaceutical preparations for administration by any suitable route. Examples include administration by oral, nasal, rectal, topical, sublingual, transdermal, intrathecal, transmucosal, or parenteral (e.g., subcutaneous, intramuscular, intravenous, and intradermal).

Pharmaceutical formulations may be prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutically acceptable carriers, diluents or excipients. Examples of excipients include water, gelatin, gum arabic, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talc, colloidal silicon dioxide, and the like. Pharmaceutically acceptable carriers include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, which are compatible with pharmaceutical administration, unless they are incompatible with the active compound.

The formulations may also contain other pharmacologically active agents and conventional additives such as stabilizers, wetting agents, emulsifiers, flavoring agents, buffers and the like.

The preparation can be prepared into dosage forms such as tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections by conventional methods. Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicle. Tablets and granules may be coated in a conventional manner.

Solutions or suspensions for parenteral, intradermal, or subcutaneous application may include sterile diluents such as water for injection, saline, fixed oils (fixed oils), polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting tonicity such as sodium chloride or dextrose. The pH can be adjusted with an acid or base, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

For oral administration, the compositions may be in the form of soft capsules or tablets, and typically include an inert diluent or an edible carrier. Oral compositions may also be prepared using a liquid carrier for use as a mouthwash, wherein the compound in the liquid carrier is applied orally and swished (swish), expectorated or swallowed. Pharmaceutically compatible binding agents and/or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, lozenges, and the like may contain any of the following ingredients, or compounds of similar nature: a binder, such as microcrystalline cellulose, gum tragacanth or gelatin; excipients, such as starch or lactose; disintegrating agents, such as alginic acid, cogel (Primogel) or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants (glidant), such as colloidal silicon dioxide; sweetening agents, such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Formulations intended for inhalation may be presented as an aerosol spray, for example, in a pressurized container or dispenser containing a suitable propellant.

Transmucosal or transdermal delivery may be used for systemic administration. The penetrants discussed as being suitable for the barrier may be used and are well known in the art. Examples include detergents, bile salts and fusidic acid derivatives. Nasal sprays and suppositories are useful for transmucosal delivery. Creams, ointments, salves and gels may be used for transdermal delivery. In the case of rectal delivery, these formulations may also be provided as retention enemas.

Formulations intended for targeted delivery of the compositions and compounds described herein may also be provided, for example, using targeting agents such as antibodies, antibody fragments, receptor binding agents, nanoparticles, nanocarriers, or combinations thereof. In this regard, it is known that cancer cells exhibit cancer specific markers, meaning that agents specific for these markers can be used to direct the compounds and compositions described herein to cancer cells and tissues in a selective manner.

In one example, the compounds described herein can be conjugated to an antibody or fragment thereof specific for one or more cancer cell-specific markers, or a nanoparticle linked to a targeting ligand specific for one or more cancer cell-specific markers. Examples of nanoparticles include lipid cationic nanoparticles, gold nanoparticles, silica nanoparticles, pegylated nanoparticles, and amphiphilic polymeric nanoparticles. Compositions can include nanoparticles having a variety of functional ligands, which can include, for example, diagnostic and/or other therapeutic agents in addition to the compounds described herein. Nanocarriers (e.g., liposomes and micelles) conjugated to targeting molecules (e.g., ligands, antibodies or antibody fragments) can be used to deliver the unmodified compounds and compositions described herein to cancer cells and tissues.

The compounds and compositions may also be provided in a formulation that prevents rapid elimination from the body. Examples include known modified release formulations such as implants and microencapsulated delivery systems.

Pharmaceutical compositions containing appropriately formulated compounds may be contained in a container, package or dispenser together with instructions for administration.

The appropriate dosage form of the formulation will depend on the intended route of administration, the amount of drug delivered, and the potential toxicity of the compound. This can be determined according to standard procedures known in the art. For example, toxicity and therapeutic efficacy of a compound can be determined by standard pharmaceutical procedures in cell cultures or experimental animals and evaluated by considering LD50 (the dose lethal to 50% of the human population), ED50 (the dose therapeutically effective in 50% of the human population), and the therapeutic index resulting therefrom (LD50/ED 50). Appropriate dosage forms may also depend on the potential side effects of the particular route of delivery, as well as the amount of active compound required to be efficiently delivered to the intended site in need of treatment.

Examples of the invention

Isolation and characterization of the dimeric compounds palatinomycin, palatinomycin B and Miyabenol

Freeze-dried young leaves of salix integra were used as starting material for the initial isolation of salix integra (fig. 1A) and miyabenol (fig. 1C). Lyophilized caulicles of Salix integra were used as starting material for the initial isolation of uteromycin B (FIG. 1B). Prior to extraction, the tissue was ground to a homogeneous powder.

Salix palaestin

To initially isolate uteromycin, 1mL of a solution of water in methanol (80:20) was added to leaf tissue of Salix integra (50 mg). The suspension was stirred at room temperature for 5 minutes, then heated to 50 ℃ in a water bath and thermostated for 10 minutes. The resulting solution was centrifuged at 13000rpm for 5 minutes, 800. mu.L of the supernatant was removed to a clean tube and heated at 90 ℃ for 2 minutes. The solution was cooled (5 ℃ C.) for 30 minutes and centrifuged at 13000rpm for 5 minutes. The supernatant containing the target compound was purified by reverse phase HPLC. The sample was repeated 6 times in analytical HPLC using an Agilent1100HPLC system equipped with a four-stage pump, diode array detector, column oven and autosampler, 100 μ Ι _ each. Chromatographic peaks were separated using an Ascentis C18 column (5um, 5X 250mm (Supelco, UK)). The operation solvent is as follows: solvent(s)A: h containing 0.1% formic acid₂O, solvent B: acetonitrile containing 0.1% formic acid. The operating gradient for peak separation was from 5% B (0-10min), 22% B (10-50min) to 37% B (60-70min), constant flow 1mL/min, and total chromatography run time 72 min. Peaks were identified and monitored at a wavelength of 254nm and collected manually into glass tubes. The oxytetracycline eluted at 57.93min (FIG. 2). Equivalent fractions from 6 runs were combined and evaporated using a Speedvac concentrator (Genevac, saffron, uk) to yield 1.68mg of purified palatinomycin. By the above procedure, products can also be recovered from the following salix genera: ramulus Salicis Babylonicae, Salix fluviatilis, Salix Salicariae, Salix Salicaceae, Salix Salicaceae, Salix Salicaceae, Salix Herbacea, and hybrid Salix Herbacea.

TABLE 2 extraction and HPLC gradient conditions for separation of dimeric metabolites

Further structural diversity was seen when analyzing the hybrid breeding lines of Salix integra (RR10347) resulting from the hybridization of NWC941 (Salix integra) with RR05326(Resolution X pseudo-tamarix). Analysis of RR10347 by LC-MS indicated the presence of triemulicin (C)₂₇H₂₈O₁₁) Which are 2' -O-benzoylated derivatives of salidroside, which is well known in the Salicaceae family. A new peak also appeared at 30.95min, with a mass of 947.2561, corresponding to the molecular formula C₄₇H₄₇O₂₁The ion of (2). As with the mass spectrum of the oxytetracycline, the smaller ion (m/z 421.1125) was associated with vitexin (salicitenone) (C)₂₀H₂₁O₁₀) The correspondence observed in (a). Other small ions (m/z 525.1465) are also evident, suggesting a formula of C₂₇H₂₅O₁₁. MSMS at m/z 947.2561 at m/z 121 (C)₇H₅O₂) And m/z 123 (C)₇H₇O₂) Two strong ions are generated, the former corresponding to the benzoate moiety and the latter to the salicylate moiety. These data suggest a novel monobenzoylated derivative of the compound of formula XVI/XVII, i.e. oxytetracycline. The peak was isolated by repeated injection into the HPLC system and purified by¹H-NMR characterizes the structure. This data confirms the presence of dimeric compounds by comparison with the NMR spectrum of the oxytetracycline. Additional peaks at δ 8.06, 7.70 and 7.54 are characteristic of benzoate groups, but doubling of most peaks indicates that the 1:1 mixture of isomers cannot be further separated. The multiple peak set appearing at δ 5.25 confirms that the 2' -position of the glucoside in the first isomer and the 2 "-position of the second isomer are substituted with benzoyl. This is in¹H-¹Further confirmation was obtained in the H-COSY spectrum.

As another example, an extended range of substituted dimeric compounds was seen in LC-MS analysis developed in a willow breeding line (RR10147) as part of the biomass improvement program of the london institute. This hybrid line comprises two parents [ RR07187(944S. glaucophylloides X577 "77056"). times RR07188(944S. glaucophyllides X577 "77056")]Ramulus Salicis Babylonicae (NWC577) and S.glucophyloids (NWC 944). In the total ion chromatogram of the negative ion mode LC-MS data, salicin, 2' -O-acetylsalicin, and terisalicin appear as the major peaks. Since this hybridization produces hybrids that produce acetylated and benzoylated salicylic acids (salicinoids) and salicin, it is expected that the relevant dimeric analogues will also be formed by a cross-reaction matrix involving the three corresponding dienones. The fact is that the occurrence of the hysteromyoma appears at 25.03min, the occurrence of the 2 '/2' -O-acetylhysteromyoma (2 '/2' -O-acetylmiyabeacon) (formula XIII/XIV) at 26.90min and the occurrence of the 2 '/2' -O-benzoylhysteromyoma (2 '/2' -O-benzoylmiyabeacon) (formula XVI/XVII) at 30.95 min. Another interesting peak was observed at 32.48min, which showed an ion of m/z 989.2617, corresponding to the formula C₄₉H₄₉O₂₂. Despite insufficient isolation, MS suggests that the predicted osiramycin analogs bear both acetyl and benzoyl substitutions.

The structure of the oxytetracycline is determined by various forms of spectroscopy. Table 3 shows the general measurement conditions for the spectroscopic analysis.

TABLE 3 general conditions and parameters for spectral measurements

Abbreviations

DEPT: distortion-free polarization transfer enhancement (method for determining carbon type (distinguishing CH)₃、CH₂CH and C)).

COSY: correlation spectrum (¹H-¹Method of H COSY).

HSQC: heteronuclear Single Quantum Coherence (Heteronuclear Single Quantum Coherence) (iii)¹H-¹³C COSY method)

HMBC: heteronuclear Multiple Bond Correlation (long range)¹H-¹³C COSY method)

Spectroscopic analysis of hysteromycin

High resolution LC-MS: LC-MS was performed in negative ion mode using a C18 column. The analysis conditions are shown in Table 3. Figure 3 shows a total ion chromatogram of purified oxytetracycline showing a single peak at 25.31 min. High resolution mass spectra were collected in negative ion mode (FIG. 4), at 843.23529 (C)₄₀H₄₃O₂₀) Shows m/z ions, corresponding to the oxytetracycline (formula C)₄₀H₄₄O₂₀) Of [ M-H ]]-. The smaller ions also appeared in the mass spectrum as m/z 889.2396 (C)₄₁H₄₅O₂₂Formate adduct), 557.1300 (C)₂₇H₂₅O₁₃)、421.1140(C₂₀H₂₁O₁₀)、331.1034(C₁₄H₁₉O₉) And 217.0507 (C)₁₂H₉O₄). MS-MS of m/z 843.23529 (FIG. 5) shows various low abundance fragments, including m/z 123.04538 (C)₇H₇O₂)、201.05629(C₁₂H₉O₃)、227.03554(C₁₃H₇O₄)、245.04494(C₁₃H₉O₅) And 557.13739 (C)₂₇H₂₅O₁₃). MS-MS (FIG. 6) of m/z 421.11404 ion is given at m/z 297.06246 (C)₁₃H₁₃O₈)、153.02017(C₇H₅O₄)、135.00946(C₇H₃O₃)、123.04583(C₇H₇O₂)、109.03004(C₆H₅O₂) And 81.03513 (C)₅H₅O) fragment(s).

NMR spectra: in a medium containing 0.01% w/v d₄-TSP as internal standard d₄Method for collecting hysteromyoma at 600MHz in aqueous methanol¹H-NMR data. The spectrum shows peaks associated with 34 coupled protons (fig. 7 and table 4).

¹ _{2 3}TABLE 4H-NMR distribution of Gongwillowycin, data collected at 600MHz in DO: CDOD (4:1), see ₄According to d-TSP (0.01% w/v)

Four signals were observed between δ 7.34-7.10, consistent with the signal obtained in the salicyl-containing compound. The integration of these arene peaks corresponds to 8 protons, indicating that there are two such salicyl rings. This is confirmed by the presence of two pairs of bimodal signals at 12Hz associated with unique salicyloxymethylene groups (1 st pair: δ 5.40 and δ 5.19; 2 nd pair: δ 5.38 and δ 5.16). Similarly, the molecule contains two different glucoside molecules, with characteristic bis-signals associated with replicated H-1 'anomeric protons (δ 5.09 and δ 5.07), identical to those corresponding to glucosyl 6' -methylene. Between δ 6.60 and 5.85 there are four independent olefin signals, each integrating one proton, two of which appear as doublets and the others as simple triplets.¹H-¹H COSY analysis (FIG. 8) showed that the two double bonds were separated from each other. Integration of the carbohydrate region (. delta.3.96-3.40) indicates a total of 16 coupled protons. Of these protons, 12 can be accounted for in two glucose units, leaving 4 unexplained.¹³The CNMR data (fig. 9 and table 5) confirm the presence of 40 carbon atoms in the molecule, including two ketonic carbonyl groups at δ 199.6 and 210.0 and two ester carbonyl groups at δ 173.6 and 173.2, whereas¹³The C DEPT135 (fig. 10) recognizes four non-aromatic methine signals in addition to the glucose (× 2) signal and the two olefin signals.

¹³ _{2 3}TABLE 5C-NMR distribution of Gongwillowycin, numbers collected at 100.61MHz in DO: CDOD (4:1) ₄According to, reference d-TSP (0.01% w/v)

Given the molecular formula from the exact mass, the similarity of the fragmentation pattern of the smaller m/z 421 fragment with the known molecule, hesperidin, and the repetition of the NMR signals associated with the benzyl and glycosyl groups, we speculate that the hysteromycin is an asymmetric dimeric structure formed by the conjugation of two molecules of the dehydro-analog of salicin. The structure has a tricyclodecadiene parent nucleus. Observed around all positions of the dimeric parent nucleus structure (FIG. 11) and between H-10(Δ 3.60) and C-8(Δ 173.6)¹H-¹³Key correlations of C HMBC (key correlations), confirm the attachment of the carboxyl group at C-9 to the parent core structure. The correlation between H-7 (. delta.5.19 and 5.40) and C-8 (. delta.173.6) confirms the binding of the salicyl moiety by the ester carbonyl. Similar correlations were also observed between H-15 (delta 03.50) and C-21 (delta 1173.2) and between H-22 (delta 5.16 and 5.38) and C-21 (delta 173.2), indicating that a second dicarboxy-salicyl entity was attached to the tricyclodecadienyl parent nucleus at C-20. Other correlations between C-1(δ 158.0) and H-7(δ 5.19 and 5.40) and H-1' (δ 5.09/5.07) and between C-28(δ 157.7) and H-22(δ 5.16 and 5.38) and H-1 "(δ 5.07/5.09) are consistent with the placement of O-glycosides at C-1 and C-28.

Salicin B

To initially isolate uteromycin B, 2.5mL of a solution of water in methanol (80:20) was added to uteromycin stem tissue (200 mg). The suspension was stirred at room temperature for 5 minutes, then heated to 50 ℃ in a water bath and thermostated for 10 minutes. The resulting solution was centrifuged at 13000rpm for 5 minutes. Remove 800. mu.L of supernatant into a clean tube and heat at 90 ℃ for 2 minutes. The solution was cooled (5 ℃ C.) for 30 minutes and centrifuged at 13000rpm for 5 minutes. The supernatant containing the target compound was purified by reverse phase HPLC. 100 μ L each was injected in analytical HPLC using an Agilent1100HPLC system equipped with a four-stage pump, diode array detector, column oven and autosampler. Chromatographic peaks were separated using an Ascentis C18 column (5um, 5X 250mm (Supelco, UK)). The operation solvent is as follows: solvent A: h containing 0.1% formic acid₂O, solvent B: acetonitrile containing 0.1% formic acid. The operating gradient for peak separation was from 5% B (0-10 mi)n), 29% B (10-60min) to 29% B (60-70min), constant flow of 1mL/min, total chromatography run time of 70 min. Peaks were identified and monitored at a wavelength of 254nm and collected manually into glass tubes. Oxytetracycline B eluted at 52.11min (fig. 12). Equivalent fractions from multiple runs were combined and evaporated using a Speedvac concentrator (Genevac, saffron, uk) to give 0.67mg of purified palatinomycin B. The structure of the oxytetracycline B was determined by various forms of spectroscopy.

Spectroscopic analysis of hysteromycin B

High resolution LC-MS: LC-MS was performed in negative ion mode using a C18 column. The analysis conditions are shown in Table 3. Fig. 13 shows a total ion chromatogram of purified oxytetracycline B, which showed a single peak at 24.34 min. High resolution mass spectra were collected in negative ion mode (FIG. 14), at 843.23474 (C)₄₀H₄₃O₂₀) Shows m/z ions, corresponding to the oxytetracycline B (formula C)₄₀H₄₄O₂₀) Of [ M-H ]]-. At m/z 889.23895 (C)₄₁H₄₅O₂₂) The smaller ion of (b) corresponds to the formate adduct.

NMR spectra: in aqueous methanol solution¹The H-NMR spectrum showed a total of 17 signals, which were associated with 34 different protons (Table 6).

¹ _{2 3}TABLE 6H-NMR distribution of Salicamycin B, data collected at 600MHz in DO: CDOD (4:1), see ₄According to d-TSP (0.01% w/v)

The presence of signals associated with benzyl and glucosyl moieties is correlated with that of oxytetracycline¹The signals observed in the H-NMR spectrum are very good compared. The loss of the four olefin signals (δ 5.91 to 6.59) previously observed in the case of the oxytetracycline was accompanied by an upward shift of the four bridgehead protons (δ 3.43-3.63), giving a set of four signals at δ 2.76, 2.88, 2.99 and 3.12, each integrating 2 protons.¹H-NMR data indicate a further [2+2 ] olefin unit in the oxytetracycline]The molecules are subjected to internal cyclization to obtain a cage-shaped structure, and the structure is named as the oxytetracycline B. Now that the cycloaddition of the double bond gives a 2-fold axis of symmetry, leads to the production of oxytetracycline B¹The H-NMR spectrum is significantly simplified relative to that observed for the case of the oxytetracycline. [¹H-¹H]Correlation spectroscopy confirmed the binding relationship around the tricyclic mother nucleus of the molecule. Table 7 shows the formula of oxytetracycline B¹³And C, data.

¹³ _{2 3}TABLE 7C-NMR distribution of Salicamycin B, numbers collected at 100.61MHz in DO: CDOD (4:1) ₄According to, reference d-TSP (0.01% w/v)

Miyabeanol

For initial isolation of Miyabenol, 2mL of a water: methanol (80:20) solution was added to the leaf tissue of the willow (150 mg). The suspension was stirred at room temperature for 5 minutes, then heated to 50 ℃ in a water bath and thermostated for 10 minutes. The resulting solution was centrifuged at 13000rpm for 5 minutes. Remove 800. mu.L of supernatant into a clean tube and heat at 90 ℃ for 2 minutes.The solution was cooled (5 ℃ C.) for 30 minutes and centrifuged at 13000rpm for 5 minutes. The supernatant containing the target compound was purified by reverse phase HPLC. The sample was repeated 8 times in analytical HPLC using an Agilent1100 PLC system equipped with a four-stage pump, diode array detector, column oven and autosampler, each 100 μ Ι _ each. Chromatographic peaks were separated using an Ascentis C18 column (5um, 5X 250mm (Supelco, UK)). The operation solvent is as follows: solvent A: h containing 0.1% formic acid₂O, solvent B: acetonitrile containing 0.1% formic acid. The operating gradient for peak separation was from 5% B (0-10min), 22% B (10-50min) to 37% B (60-70min), constant flow 1mL/min, and total chromatography run time 72 min. Peaks were identified and monitored at a wavelength of 254nm and collected manually into glass tubes. Miyabenol eluted at 44.87min (FIG. 1). Equivalent fractions from 8 runs were combined and evaporated using a Speedvac concentrator (Genevac, saffron, uk) to give 1.05mg of purified miyabenol.

Spectral analysis of Miyabenol

High resolution LC-MS: LC-MS was performed in negative ion mode using a C18 column. The analysis conditions are shown in Table 3. Figure 15 shows a total ion chromatogram of purified oxytetracycline B, which showed a single peak at 20.11 min. High resolution mass spectra were collected in negative ion mode (FIG. 16), at 531.15074 (C)₂₆H₂₇O₁₂) Shows m/z ions, corresponding to miyabenol (formula C)₂₆H₂₈O₁₂) Of [ M-H ]]-。421.11421(C₂₀H₂₁O₁₀) And 467.11943 (C)₂₁H₂₃O₁₂) The additional ion corresponds to the product of the inverse Diels Alder reaction (vitexin) and its corresponding formate adduct. MSMS analysis of m/z 531.15074 (FIG. 17) yielded 245.04634 (C)₁₃H₉O₅)、217.05150(C₁₂H₉O₄) And 123.04579 (C)₇H₇O₂) Fragment ions of (c).

NMR spectra: of miyabenol¹The H NMR spectrum (fig. 18 and table 8) shows a structure similar to the cyclic dimer, e.g., oxytetracycline, although some regions of the spectrum (including regions associated with benzyl and glucosyl groups) are not repeated, indicating that eachOne of these units has been lost.

¹ _{2 3}TABLE 8H-NMR distribution of miyabenol, data collected at 600MHz in DO: CDOD (4:1), ₄reference d-TSP (0.01% w/v)

Delta 6.63 and delta 6.02¹The H signal is consistent with that observed in oxytetracycline and is associated with enone protons, H-12 and H-13. Signals corresponding to separated olefin protons also appear at δ 6.27 and δ 5.94. This data and the addition of these signals to the other 4 methine protons¹H-¹The correlation of H COSY (FIG. 19) confirms that the molecule retains the Diels-Alder "core".¹³CNMR (fig. 20 and table 9) shows 26 different carbon signals, including two ketone signals at δ 213.29 and δ 199.1.

¹³ _{2 3}TABLE 9C-NMR distribution of miyabenol, collected at 100.61MHz in DO: CDOD (4:1) ₄Data, see d-TSP (0.01% w/v)

The location of the side chain deletion and decarboxylation was confirmed by extensive analysis of COSY, HSQC and HMBC related spectra. Key was identified between H-10 and C-8, H-10 to C-14 and H-13 to C-9¹H-¹³C correlation. This allows the carboxy-salicylglycoside moiety to be located at C-9. There are correlations from H-15 and H-18 to the carbonyl at C-19 and from H-16, H-18 and H-10 to C-20 (. delta.81.4).

Bioassay data for oxytetracycline

The activity of the hysteromyoma was tested against a range of cancer cell lines including neuroblastoma and breast, esophageal and ovarian cancers (table 10).

TABLE 10 biological Activity data of Salix integramycin in six cancer cell lines

The MYCN-expanded neuroblastoma cell line UKF-NB-3 was established from stage 4 neuroblastoma patients (Kotchetkov et al, 2005). Also tested was vincristine-resistant UKF-NB-3 subline UKF-NB-3^rVCR (Rothwell et al, 2010) (adapted to grow in the presence of 10ng/mL vincristine). UKF-NB-3 at 20. mu.g/mL was found to have a cell viability of 0% after 120 hours relative to untreated cells, while vincristine-resistant UKF-NB-3^rThe VCR is 4.22 + -2.89%. The esophageal cancer cell line COLO-680N was obtained from ATCC (Manassas, VA, USA), and the ovarian cancer cell line COLO-704 was obtained from DSMZ (Brenrek, Germany). All cell lines were propagated at 37 ℃ in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FCS, 100IU/ml penicillin and 100mg/ml streptomycin. Cells were routinely tested for mycoplasma contamination and identified by short tandem repeat analysis. Cell viability was determined by the 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT) dye reduction assay after 120h incubation as described previously (Michaelis et al, 2015). Briefly, 5000 cells (suspended in 100. mu.L of enriched 10% FCS, 100IU/ml penicillin and 100mg/ml of chain) were addedIMDM of a mycin) in the absence or presence of varying concentrations of compound at 37 ℃ and 5% CO₂The culture was carried out in a 96-well plate for 120 hours. Then, 25. mu.L of MTT solution (2. mu.g/mL in PBS) was added dropwise over 4 h. Subsequently, 100. mu.L of 20% sodium dodecylsulfate (50:50 purified water/DMF) solution was added to adjust pH to 4.7, and the reaction was continued for 4 hours to lyse the cells and dissolve formazan (formazan) precipitate. The plate was then read at 600 nm. Relative viability was determined as the relative reduction in optical density relative to untreated cell controls (═ 100%). Duplicate IC 50 values for Salix integramycin activity were determined on three selected lines (UKF-NB-3, COLO-680N and COLO-704) ranging from 17.15. mu.M to 40.18. mu.M (Table 11).

TABLE 11 IC replicates in three cancer cell lines 50 measurement

Although these results are important for all cell lines described above, of particular note is the activity on neuroblastoma cell lines. The overall survival rate of neuroblastoma is less than 50%, and it represents the most common extracranial solid tumor in children. Since the acquisition of drug resistance is an important problem of neuroblastoma, new compounds effective against neuroblastoma are highly desired.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended to cover in the appended claims such changes and modifications.

Reference to the literature

Kotchetkov R，Driever PH，Cinatl J，Michaelis M，Karaskova J，Blaheta R，Squire JA，VonDeimling A，Moog J，Cinatl J Jr.Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.Int J Oncol.2005Oct；27(4)：1029-37.

Michaelis M，Rothweiler F，Barth S，Cinatl J，van Rikxoort M，N，Voges Y，Breitling R，von Deimling A，F，Weber K，Fehse B，Mack E，Stiewe T，Doerr HW，Speidel D，Cinatl J Jr.Adaptation of cancer cells from different entities to the MDM2inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Cell Death Dis.2011Dec 15；2：e243.

Michaelis M，Agha B，Rothweiler F，N，Voges Y，Mittelbronn M，Starzetz T，Harter PN，Abhari BA，Fulda S，Westermann F，Riecken K，Spek S，Langer K，Wiese M，Dirks WG，Zehner R，Cinatl J，Wass MN，Cinatl J Jr.Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.Sci Rep.2015a Feb3；5：8202.

Rothwell，P.M.，et al.Long-term effect of aspirin on colorectal cancer incidence and mortality：20-year follow-up of five randomised trials.Lancet 376：1741-50(2010).

The contents of all references cited herein are incorporated by reference in their entirety.